Research Article | Volume: 5, Issue: 1, Jan-Feb, 2017

Characterization of the pscC (Type III secretion) gene of Pseudomonas aeruginosa (PA01) and assessment of immunogenicity of pscC protein in rats

Md Safiul Alam Bhuiyan Hafiza Sultana Kenneth Francis Rodrigues Fernandes Opook   

Open Access   

Published:  Jan 20, 2017

DOI: 10.7324/JABB.2017.50106

Proteins associated with the bacterial membrane can be recruited for application as antigens for the development of vaccines. This preliminary study was directed towards evaluating the antigenic properties of the Pseudomonas aeruginosa (PA01) pscC protein which is a component of the Type III secretion system. Gene specific primers were designed to isolate the pscC gene which was isolated, ligated onto the multiple cloning site of vector pGS21(a), cloned and expressed in Escherichia coli (BL21). The molecular weight of the expressed pscC protein was determined by SDS-PAGE (10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and was found to be around 57 KDa and purified by the size exclusion chromatography. Finally, the purified pscC protein was injected subcutaneously into adult Sprague Dawley® rats with a range of concentrations (50, 100 and 150 µg per rat) respectively. Recombinant pscC antigen induced a specific humoral immune response against the antigen, which was validated by Enzyme-linked immunosorbent assay (ELISA). The results concluded that anti-pscC antibody was elicited in the animal model.

Keyword:     Pseudomonas aeruginosapscC genetype III secretion system.


Bhuiyan SA, Sultana H, Opook, F Rodrigues KF. Characterization of the pscC (Type III secretion) gene of Pseudomonas aeruginosa (PA01) and assessment of immunogenicity of pscC protein in rats. J App Biol Biotech. 2017; 5 (01): 035-041. DOI: 10.7324/JABB.2017.50106

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

HTML Full Text

1. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis, and treatment of Pseudomonas aeruginosa infections. Drugs. 2007; 67: 351-368.

2. Daniels C, Griffiths C, Cowles B, Lam J. Pseudomonas aeruginosa O-antigen chain length is determined before ligation to lipid a core. Environmental Microbiology. 2002; 4: 883-897.

3. Bernhardt TG, Wang IN, Struck DK, Young R. Breaking free: "protein antibiotics" and phage lysis. Research Journal of Microbiology. 2002; 153: 493-501.

4. Zhang, L, Li XZ, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug resistant Pseudomonas aeruginosa, Stenotrophmonas maltophila and Burkholderia cepacia. Journal of Antimicrobial Chemotherapy. 2001; 48: 549-552.

5. Cryz, SJ Jr, Pitt TL, Furer E, Germanier R. Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infection and Immunity. 1984; 44: 508-513.

6. Ruano-Gallego D, Álvarez B, Fernández LÁ. Engineering the Controlled Assembly of Filamentous Injectisomes in E. coli K-12 for Protein Translocation into Mammalian Cells. ACS synthetic biology. 2015; 4:1030-1041.

7. Amanna I, Slifka M. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Journal of Virology. 2011; 411: 206-215.

8. Chen LM, Briones G, Donis RO, Galan JE. Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infection and Immunity. 2006; 74: 5826-5833.

9. Galan JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature. 2006; 444: 567-573.

10. Perez O, Batista-Duharte A, Gonzalez E, Zayas C, Balboa J, Cuello M, Cabrera O, Lastre M, Schijns VE. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Brazilian Journal of Medical and Biological Research. 2012; 45: 681-692.

11. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Brazilian Journal of Medical and Biological Research. 2012; 45:1102-1111.

12. Buatois V, Baillet M, Becart S, Mooney N, Leserman L, Machy P. MHC class II-peptide complexes in dendritic cell lipid microdomainsinitiate the CD4 Th1 phenotype. The Journal of Immunology. 2003; 171: 5812-5819.

13. Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. The Journal of Infectious Diseases. 2013; 208(12): 1953-1961.

14. Stober D, Trobonjaca Z, Reimann J, Schirmbeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. European Journal of Immunology. 2002; 32: 1099-1108.

15. Aljanabi SM, Martinez I. Universal and rapid salt-extraction of high quality genomic DNA for PCR based techniques. Nucleic Acids Research. 1997; 25: 4692-4693.

16. Li X, Sui X, Zhang Y, Sun Y, Zhao Y, Zhai Y, Wang Q. An improvised calcium chloride method preparation and transformation of competent cells. African Journal of Biotechnology. 2010; 9:8549-8554.

17. Bringans S, Eriksen S, Kendrick T, Gopalakrishnakone P, Livk A, Lock R, Lipscombe R. Proteomic analyses of the venom of Heterometrus longimanus (Asian black scorpion). Proteomics. 2008; 8: 1084-1096.

18. Wessel D, Flugge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergent and lipids. Analytical Biochemistry. 1984; 138: 141-143.

19. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009; 27(6): G38-G46.

20. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clinical and Vaccine Immunology. 2012; 19:377-385.

21. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: prospective immunizations by parenteral, mucosal and gene-gun inoculations. Proceedings of the National Academy of Sciences USA. 1993; 90: 11478-11482.

22. Cripps AW, Dunkley ML, Clancy RL. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infection and Immunity. 1994; 62: 1427-1436.

23. Lee N, Ahn B, Kim YG, Kim H, Park WJ. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans. FEMS Immunology and Medical Microbiology. 2000; 27: 79-85.

24. Robinson HL, Ginsberg HS, Davis HL, Johnston, SA, Liu MA. The scientific future of DNA for immunization. American Academy of Microbiology critical issues colloquia. Washington, DC; 1997.

25. Gilleland HE, Gilleland LB, Staczek J, Harty RN, Garcia-Sastre A, Palase P, Brennan FR, Hamilton WD, Bendahmane M, Beachy RN. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. FEMS Immunology and Medical Microbiology. 2000; 27:291-297.

26. Anderson R, Gao XM, Papakonstantinopoulou A, Roberts M, Dougan G. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infection and Immunity. 1996; 64: 3168-3173.

27. Barry MA, Lai WC, Johnston SA. Protection against Mycoplasma infection using expression-library immunization. Nature. 1995; 377: 632-635.

28. Paul W, Reena V, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury, Sellman B, Stover CK. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrobial Agents and Chemotherapy. 2014; 58:4384-4391.

29. Brian M, Price, Darrell R, Galloway, Harry E, Gilleland. Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. aeruginosa. Infection and Immunity. 2001; 69 (5): 3510-3515.

30. Mingzi J, Jing Y, Ganzhu F. Protective effect of DNA vaccine encoding Pseudomonas exotoxin against acute pulmonary Pseudomonas aeruginosa infection. PLOS Pathogen. 2014; 9(5): e96609.

31. Fox CW, Campbell GD, Anderson MM, Zavecz JH, Gilleland LB, Gilleland HE. Preservation of pulmonary function by an outer membrane protein F vaccine: a study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa. Chest. 1994; 105: 1545-1550.

Article Metrics

211 Absract views 201 PDF Downloads 412 Total views

Related Search

By author names

Citiaion Alert By Google Scholar

Similar Articles